Novel educational video module about alcohol use disorder increases treatment rates and decreases return to alcohol use

Table 1 Demographics and clinical characteristics, n (%)

Characteristic	Patient total (n = 52)
Age
N (missing)	52 (0)
Median (IQR)	45.0 (35.5, 51.5)
Sex
Female	26 (50.0)
Male	26 (50.0)
Ethnicity
African	1 (1.9)
African American	6 (11.5)
Caucasian	31 (59.6)
Hispanic	11 (21.2)
Native American	1 (1.9)
Other	2 (3.8)
Insurance
Medicaid	8 (15.4)
Medicare	12 (23.1)
None	8 (15.4)
Private	19 (36.5)
Self-pay	5 (9.6)
Marital status
Not married	41 (78.8)
Married	11 (21.2)
Liver disease
Alcohol hepatitis	22 (42.3)
Cirrhosis	21 (40.4)
Steatosis	9 (17.3)
MELD-Na
N (missing)	46 (6)
Median (IQR)	15.5 (10.0, 25.0)
Hepatic encephalopathy
No	45 (86.5)
Yes	7 (13.5)
Ascites
No	30 (57.7)
Yes	22 (42.3)
Esophageal varices
No	40 (76.9)
Yes	12 (23.1)
Hepatocellular carcinoma
No	52 (100.0)
Self-reported drinks
N (missing)	52 (0)
Median (IQR)	8.0 (3.0, 22.0)
Ethanol
N (missing)	48 (4)
Median (IQR)	71.0 (0.0, 224.0)
Phosphatidylethanol (pETH)
N (missing)	26 (26)
Median (IQR)	356.5 (51.0, 917.0)
Withdrawal
No	21 (40.4)
Yes	31 (59.6)
Previous pharmacologic treatment
No	38 (73.1)
Yes	14 (26.9)
Acamprosate
No	49 (94.2)
Yes	3 (5.8)
Disulfiram
No	52 (100.0)
Naltrexone
No	42 (80.8)
Yes	10 (19.2)
Vivitrol
No	42 (80.8)
Yes	10 (19.2)
Previous behavioral treatment
No	33 (63.5)
Yes	19 (36.5)
Inpatient treatment
No	44 (84.6)
Yes	8 (15.4)
Outpatient treatment
No	44 (84.6)
Yes	8 (15.4)
Mutual aid
No	37 (71.2)
Yes	15 (28.8)
Behavioral and pharmacologic treatment
No	46 (88.5)
Yes	6 (11.5)
Seen by addiction psychiatry
No	16 (30.8)
Yes	36 (69.2)
Seen by GI
No	17 (32.7)
Yes	35 (67.3)

N (missing): Number of patients (missing patients); IQR: Interquartile range; MELD-Na: Model for end-stage liver disease; pETH: Phosphatidylethanol level; GI: Gastrointestina.